Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a COPD flare stun the heart? study watches for hidden strain

NCT ID NCT06597331

Knowledge-focused Sponsor: Sahlgrenska University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers at Sahlgrenska University Hospital in Sweden are observing 200 adults hospitalized for a severe COPD flare-up to see how often the condition triggers a temporary heart muscle weakness called Takotsubo stunning. They will use echocardiograms to check heart function at admission and again on day 1 and day 30, and track signs of acute heart failure and other heart problems during the hospital stay. The study compares patients who develop heart stunning with those who do not, aiming to understand whether this complication worsens outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the link holds, doctors could monitor COPD flare-ups for hidden heart strain and treat it earlier, possibly preventing heart failure during hospitalization.
What could go wrong
This observational study cannot prove cause and effect, and it takes place at one hospital in Sweden, so the findings may not apply broadly. The heart imaging and follow-up may also miss subtle cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients admitted to hospital ward for AE-COPD within 72 hours

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥ 18 years old) admitted to hospital ward for AE-COPD * Inclusion within 72 hours of admission, * Written informed consent Exclusion Criteria: * Prior acute myocardial infarction or known pre-existing persistent regional wall motion abnormality or left ventricular dysfunction (left ventricular ejection fraction \[LVEF\] \<50%) * Expected inability to comply with the protocol (e.g. dementia)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease heart failure Tako-tsubo cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure Chronic obstructive pulmonary disease Takotsubo cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Emergency Medicine and Geriatrics, Sahlgrenska University Hospital/S

    RECRUITING

    Gothenburg, Region Västra Götaland, 41345, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.